VISTASEAL: payments to doctors
Payments that named VISTASEAL as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.1M
- Providers
- 11,861
- Transactions
- 19,727
- Average per transaction
- $157
The per-transaction average — $157 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 11,861 providers the average total is $261, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $1,791,688 | 57.8% |
| Medical Device Business Services, Inc. | $1,291,069 | 41.7% |
| Ethicon Endo-surgery Inc. | $9,715 | 0.3% |
| Depuy Synthes Products, Inc. | $3,751 | 0.1% |
| Johnson And Johnson International | $2,701 | 0.1% |
| Johnson & Johnson Surgical Vision, Inc. | $604 | 0.0% |